Get Started
HBV Curricula
Step 1




The Advanced Certificate Program in Chronic Hepatitis B Management V
Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
Co-Chairs
faculty image
Adrian M. Di Bisceglie, MD, FACP
  • Chairman, Internal Medicine
  • Chief of Hepatology
  • Saint Louis University School of Medicine
  • St. Louis, Missouri
    • faculty image
    Robert G. Gish, MD
  • Medical Director
  • Center for Hepatobiliary Disease and Abdominal Transplantation
  • Chief of Hepatology
  • Professor of Medicine
  • University of California San Diego
  • San Diego, California
    • Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chair this free, yearlong CME/CE program featuring the very latest information on screening and current and emerging treatment strategies for HBV management. Get clarity and guidance from prominent hepatology experts on key issues and practice challenges, including how cultural differences can affect physician/patient communications, thus impacting the management of HBV infection. Earn CME/CE credit and complete all courses to earn your Certificate of Advanced Study.

  • Assess screening, diagnosis, prevention strategies (eg, vaccination), and optimal treatment interventions of patients with or at risk of chronic HBV infection through an understanding of the epidemiology, risk factors, and disease burden imposed by HBV infection.
  • Analyze cultural differences in patient communication and management of HBV infection (comparing the Asian and Pacific-Islander, Latino, black, and white communities) to bridge these differences and improve patient outcomes.
  • Assess status of molecular tests in determining when to treat, optimal treatment selection and on-treatment response in chronic HBV-infected patients with diverse ethnic backgrounds to improve patient outcomes.
  • Formulate anti-HBV treatment strategies, considering efficacy, therapeutic endpoints, safety, and resistance profiles of current and emerging antiviral agents to improve response rates in culturally diverse patients with chronic HBV infection.
  • Implement optimal treatment selection for special populations with chronic HBV infection to improve outcomes.
  • Integrate personalized anti-HBV prescribing, treatment, and monitoring strategies to prevent, reduce, or manage drug resistance in patients with chronic HBV infection.
  • Analyze barriers to initiating timely anti-HBV treatment interventions and strategies to overcome these barriers in the practice setting.
  • Implement monitoring and follow-up to optimize anti-HBV therapy response for improved patient outcomes (prevent/manage drug resistance, identify/manage therapy-related side effects ensure adherence).
    • AASLD, Keeffe, and APASL HBV Treatment Guidelines
    • Treatments
      • Interferon and Ribavirin-based Therapy
      • Oral Nucleosides/Nucleotides
      • Investigational Drugs
      • Combination Therapy
    • Treatment Endpoints and Duration
    • Monitoring for Treatment Response
    • Screening for HBV (including CDC guidelines)
    • AASLD, Keeffe, and APASL Hepatitis B virus Treatment Guidelines (including updates)
    • HBV virology and genotyping
    • Assessing At-Risk Individuals for HBV - Special Populations
    • Screening and Diagnosis in the Asian Community
    • Chronic HBV Disease Burden
    • HBV Treatment Options and Strategies
    • HBV Treatment Resistance - Detection and Management

    Target Audience

    This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, as well as nurse practitioners, nurses, physician assistants, and pharmacists, who specialize in and care for patients with HBV.

     

    Activity Goal

    The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.